MCP
PRLD icon

Militia Capital Partners’s Prelude Therapeutics PRLD Stock Holding History

Militia Capital Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,300
Closed -$3.3K – 212
2025
Q1 		$3.3K Hold
4,300
– – ﹤0.01% 141
2024
Q4 		$5.48K Buy
+4,300
New +$5.71K ﹤0.01% 204

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Militia Capital Partners's PRLD Position: Q2 2025 in Review

Militia Capital Partners sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 4,300 shares — an estimated $3.3K sold.

Militia Capital Partners first reported a position in PRLD in Q4 2024 and held it in 2 quarters. The position peaked at $5.48K in Q4 2024. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Militia Capital Partners reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Militia Capital Partners sold 4,300 Prelude Therapeutics shares in Q2 2025, an estimated $3.3K.
  • Militia Capital Partners first reported a position in Prelude Therapeutics in Q4 2024 and held it in 2 quarters.
  • Militia Capital Partners's Prelude Therapeutics position peaked at $5.48K in Q4 2024.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Militia Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.